## **Supplementary Information**

## Irritable bowel syndrome-related differences in the fecal microbiome and metabolome are not affected by short-term improvement after the rifaximin treatment

Natalia Zeber-Lubecka<sup>1#</sup>, Maria Kulecka<sup>1#</sup>, Filip Ambrozkiewicz<sup>1</sup>, Agnieszka Paziewska<sup>1</sup>, Krzysztof Goryca<sup>2</sup>, Jakub Karczmarski<sup>2</sup>, Tymon Rubel<sup>3</sup>, Wojciech Wojtowicz<sup>4</sup>, Piotr Mlynarz<sup>4</sup>, Lukasz Marczak<sup>5</sup>, Roman Tomecki<sup>1</sup>, Michal Mikula<sup>2</sup>, Jerzy Ostrowski<sup>1,2,\*</sup>

<sup>1</sup> Department of Gastroenterology, Hepatology and Clinical Oncology, Medical Center for Postgraduate Education; Warsaw, Poland

<sup>2</sup> Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology; Warsaw, Poland


<sup>3</sup> Institute of Radioelectronics, Warsaw University of Technology, Warsaw, Poland

<sup>4</sup> Department of Bioorganic Chemistry Wroclaw University of Technology, Wroclaw, Poland

<sup>5</sup> Institute of Bioorganic Chemistry Polish Academy of Sciences, Poznań, Poland


#equal contribution
\*corresponding author
Jerzy Ostrowski, MD, PhD; Cancer Center-Institute, Roentgena 5, 02-781 Warsaw, Poland,
Tel: +48 225462575, Fax: +48 225462449, E-mail: jostrow@warman.com.pl

**Figure S1.** *Bacteroidetes/Firmicutes* ratios in healthy controls (HCs) and IBS patients before (IBS) and after (Treatment) treatment.




**BACTEROIDETES/FIRMICUTES RATIO** 

**Figure S2.** PCA plot of IBS patients (D: Diarrhea subgroup; C: Constipation subgroup; M: Mixed symptoms subgroup) before treatment and healthy controls (HC).




**Figure S3.** PCA plot of IBS patients before treatment and healthy controls on a functional level, based on KEGG pathway assignment to bacterial taxa. IBS subgroup (D: Diarrhea; C: Constipation; M: Mixed symptoms) and healthy controls (HC).




Pathway	Abbreviation				
Arginine and proline metabolism	Aapm				
Fructose and mannose metabolism	Famm				
Lipopolysaccharide biosynthesis	Lppb				
Lipopolysaccharide biosynthesis proteins	Lpbp				
Methane metabolism	Mthm				
Peptidoglycan biosynthesis	Pptb				
Porphyrin and chlorophyll metabolism	Pacm				
Purine metabolism	Prnm				
Pyrimidine metabolism	Pyrmm				
Pyruvate metabolism	Pyrvm				
Starch and sucrose metabolism	Sasm				
Toluene degradation	Tlnd				
Ubiquinone and other terpenoid-quinone biosynthesis	Uaotb				
Valine, leucine, and isoleucine biosynthesis	Vlaib				

**Figure S4.** Boxplot of abundances of 15 of the most abundant metabolic pathways, split by IBS type (including healthy controls). IBS subgroup (D: Diarrhea; C: Constipation; M: Mixed symptoms) and healthy controls (HC).




Pathway	Abbreviation					
Alanine, aspartate, and glutamate metabolism	Aaagm					
Amino acid-related enzymes	Aare					
Amino sugar and nucleotide sugar metabolism	Asansm					
Arginine and proline metabolism	Aapm					
Carbon fixation pathways in prokaryotes	Cfpip					
Cysteine and methionine metabolism	Camm					
Fructose and mannose metabolism	Famm					
Glycolysis/Gluconeogenesis	Gl/G					
Methane metabolism	Mthm					
Oxidative phosphorylation	Oxdp					
Peptidases	Pptd					
Purine metabolism	Prnm					
Pyrimidine metabolism	Pyrmm					
Pyruvate metabolism	Pyrvm					
Starch and sucrose metabolism	Sasm					


**Figure S5.** Representative <sup>1</sup>HNMR spectra of fecal samples in  $CDCl_3$  at 300° K in (A) a healthy control (HC) and (B) a patient with IBS



**Figure S6.** Distribution of the GC-MS measurements of samples from healthy controls (HCs) and IBS patients before treatment (IBS-M, IBS-D, and IBS-C) on the plane spanned by the two first principal components. The PC scores were computed for 13 metabolites exhibiting significant pairwise abundance changes between the studied groups (Table S2).



**Figure S7.** Distribution of the GC-MS measurements of samples from healthy controls (HCs) and IBS patients after treatment (IBS-M II, IBS-D II, and IBS-C II) on the plane spanned by the two first principal components. The PC scores were computed for 13 metabolites exhibiting significant pairwise abundance changes between the studied groups (Table S3).



indicité résolution du seu analysis of récui sampres.										
Comparison	Sample	$R^2X(cum)$	$Q^2(cum)$	р	Number of					
	number			value	latent					
					variables					
HC vs. IBS I	30	0.497	0.372	0.02	2					
HC vs. IBS II	32	0.475	0.109	0.71	2					
IBS II <sub>n</sub> vs IBS	26	0.481	-0.0931	1	2					
II										
HC vs. IBS-C	8	0.352	0.468	0.17	1					
II										
HC vs. IBS-D	20	0.509	0.207	0.45	2					
II										
HC vs. IBS-M	20	0.549	0.00579	1	2					
Π										

**Table S1.** Partial least-squares-discriminant analysis models obtained from proton nuclear magnetic resonance-based analysis of fecal samples.

HC: healthy control; IBS-D: Diarrhea subgroup, before treatment (DI), after treatment with improvement (DII); IBS-C: Constipation subgroup, before treatment (CI), after treatment with improvement (CII); IBS-M: Mixed symptoms subgroup, before treatment (MI), after treatment with improvement (MII); IBS II<sub>n</sub>: IBS patients with no improvement; IBS II: IBS patients with improvement

	ANOVA	OVA IBS-D vs. HC			IBS-M vs. HC IBS			IBS-D vs. IBS-C		IBS-M vs IBS-C		IBS-D vs I	BS-M
	p-value	p-value	FC	p-value	FC	p-value	FC	p-value	FC	p-value	FC	p-value	FC
Tocopherol-t-tms-derivative	0.0102	0.0029	0.28	0.0213	0.5			0.0024	0.14	0.0016	0.26	0.0399	0.56
1H-Indole, 3-methyl-1- (trimethylsilyl)-	0.0325	0.0004	4.18	0.0053	2.6			0.0186	3.06				
N,O-Bis- (trimethylsilyl)phenylalanine	0.0358	0.0024	18.34	0.0006	6.7								
d-Glucose, 2,3,4,5,6-pentakis- O-(trimethylsilyl)-, o- methyloxyme, (1Z)-	0.0358	0.0052	13.01	0.0002	7.66								
Pyrimidine, 2,4- bis[(trimethylsilyl)oxy]-	0.0358	0.0017	6.96	0.0012	10.02								
Eicosanoic acid, trimethylsilyl ester	0.0358	0.0109	0.37	0.0035	0.39			0.0337	0.4	0.0063	0.42		
Silane, tetramethyl-	0.0451			0.0018	0.5							0.0318	1.44
2-Desoxy-pentos-3-ulose, bis(methoxime),O,O'- bis(trimethylsilyl)-	0.0558	0.0010	0.38	0.0001	0.4								
E-2- Hydroxymethylcyclopentanol, di(trimethylsilyl) ether	0.0692					0.0212	0.25	0.0041	9.69	0.0074	6.5		
Dodecanoic acid, trimethylsilyl ester	0.0812			0.0024	0.07							0.0244	2.92
l-Alanine, trimethylsilyl ester	0.0812	0.0061	2.75	0.0076	2.92								
n-Pentadecanoic acid, trimethylsilyl ester	0.0812			0.0267	0.5					0.0049	0.36		
Heptadecanoic acid, trimethylsilyl ester	0.0844			0.0335	0.51			0.0328	0.4	0.0030	0.28		

**Table S2.** List of 13 metabolites exhibiting significant (FDR,  $\leq 0.1$ , and FC,  $\geq 1.5$ ) differences in abundance between healthy controls (HCs) and the three subgroups of IBS patients before treatment (IBS-M, IBS-D, and IBS-C).

**Table S3.** List of 13 metabolites exhibiting significant (FDR,  $\leq 0.1$ , and FC,  $\geq 1.5$ ) differences in abundance changes between healthy controls (HCs) and the three subgroups of IBS patients after treatment (IBS-M II, IBS-D II, and IBS-C II). Positions marked in bold indicate metabolites that also differed significantly before treatment.

Matahalita nama	ANOVA	VA IBS-D II vs. HC		IBS-M II vs. HC		IBS-C II vs. HC		IBS-D II vs. IBS-C		IBS-M II vs IBS-C		IBS-D II vs IBS-M	
Metabolite name	p-value	p-value	FC	p-value	FC	p-value	FC	p-value	FC	p-value	FC	p-value	FC
Propanoic acid, 2-	·	-		-		•		-		-		-	
(methoxyimino)-,													
trimethylsilyl ester	0.0011	0.0070	0.7	0.0000	0.4	0.0027	0.6					0.0133	1.5
Nonanoic acid, trimethylsilyl													
ester	0.0455	0.0013	0.3									0.0021	0.5
Pyrimidine, 2,4-													
bis[(trimethylsilyl)oxy]-	0.0455			0.0001	5.6	0.0021	6.0						
N,O-Bis-													
(trimethylsilyl)phenylalanine	0.0455	0.0016	9.1	0.0017	13.0	0.0019	4.3						
Pentasiloxane, dodecamethyl-	0.0455	0.0289	0.7							0.0233	2.2	0.0040	0.5
d-Glucose, 2,3,4,5,6-pentakis-													
O-(trimethylsilyl)-, o-													
methyloxyme, (1Z)-	0.0455	0.0068	13.5	0.0007	10.6	0.0228	3.4						
1H-Indole, 3-methyl-1-													
(trimethylsilyl)-	0.0455	0.0124	3.8	0.0010	3.7	0.0117	2.6						
2-Desoxy-pentos-3-ulose,													
bis(methoxime),O,O'-													
bis(trimethylsilyl)-	0.0455			0.0024	0.5					0.0222	0.3	0.0103	3.0
1,2-Benzenediol													
bis(trimethylsilyl) ether	0.0455			0.0640	1.6	0.0338	0.7			0.0045	2.3	0.0109	0.6
Cyclopentanecarboxylic acid,													
1-amino-, bis(trimethylsilyl)													
deriv.	0.0455	0.0179	2.9	0.0031	3.1			0.0591	2.8	0.0172	3.1		
Tocopherol-τ-tms-derivative	0.0455	0.0002	0.3					0.0017	0.3				
Heptadecanoic acid,													
trimethylsilyl ester	0.0491	0.0102	0.3	0.0444	0.6			0.0091	0.3	0.0327	0.6		
n-Pentadecanoic acid,													
trimethylsilyl ester	0.0617			0.0076	0.4					0.0149	0.4		